ESTROGEN AND PROGESTERONE HORMONE RECEPTORS FOR BREAST CANCER TREATMENT

الملخص

Background: Breast cancer is a heterogeneous and hormone-dependent disease. Screening for the estrogen receptor (ER) and progesterone receptor (PgR) is critical for prognosis assessment and treatment selection for breast cancer for clinical practice. The purpose of this study was to evaluate the expression and distribution of hormonal receptors and their association with clinical diagnostic criteria to improve the treatment of patients in Libya.

Methods: A total study included 114 Libyan female breast carcinoma. who were diagnosed between January 2020 to July 2022 in the hospital medical laboratory in Tripoli. Where it, the paraffin-embedded blocks of these patients were examined by immunohistochemistry to assess ER and PgR status. Microsoft Excel was used to analyze the data.

Results:

Mean age of the cases was 45 years ranging from women 54.4% cases had positive history of breast cancers in first degree, were as patients more than years old. Out of 114 Libyan female breast carcinoma, 45 patient have right side, while left side detected in 69 cases, more over from recorded breast carcinoma there were 9 patient in the 1st stage breast carcinoma, 73 patients in the 2ed stage, 31 patients in the 3th stage breast carcinoma. Out of 114 patients, 28 patients have metastatic breast carcinoma, while 86 patient of them were not. The ER+PgR+ group was dominant with 86(75%) cases, followed by 28(24.6%) ER-PgR-. As for progressed diseases 13 cases (11.4% ).

Conclusion:

The ER+PgR+ and ER-PgR- are the most common subgroups in women with breast cancer in Libya. The hormonal receptor status is associated with the age and the histologic grade in breast cancer patients. The systematic use of hormonal treatment should be revaluated. A further study should be done to investigate the reasons of high rate of ER- PgR- in breast cancer patients in Libya.